Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome

This quasi-experimental study, conducted at the department of Pediatric Nephrology & Nephrology, National Institute of Kidney Diseases & Urology, Dhaka, aimed to evaluate the effectiveness and safety of atorvastatin therapy in children with dyslipidemia in steroid-sensitive nephrotic syndrome (SSNS). The study enrolled 100 children aged between 8-18 years with SSNS and dyslipidemia. The background notes that dyslipidemia is a common complication in children with SSNS, often persists during remission, and increases the risk of early atherosclerosis, cardiovascular disease, and progressive kidney damage. It states that lifestyle and dietary measures are often insufficient and that evidence on statin use in this population remains fairly unexplored. The primary outcome measure was the percentage of patients achieving target levels of lipid profile. The study status is listed as COMPLETED, with a start date of January 27, 2024, and a primary completion date of August 30, 2025. The abstract does not provide any specific numerical results regarding the primary outcome, changes in lipid parameters, safety signals, adverse events, or statistical analyses (such as p-values, confidence intervals, hazard ratios, or odds ratios). No limitations of the study are mentioned in the provided abstract text.